LIPID PROFILE IN PATIENTS WITH ISCHEMIC HEART DISEASE DEPENDING ON BsmI AND FokI POLYMORPHISMS OF THE VDR GENE AND THE VITAMIN D CONTENT

The objective of the study was to compare the level of plasma lipids in different genotypes of the polymorphic markers BsmI (B/b) (rs1544 410) and FokI (F/f) (rs2 228570) of the vitamin D receptor gene (VDR) taking into account the D vitamin content in persons with coronary heart disease (CHD).

97 patients (43 men, 54 women) with CHD were examined. The BsmI and FokI polymorphisms of VDR genes were determined by the polymerase chain reaction. Concentration of vitamin D (25(OH)D) in blood plasma was determined by enzyme immunoassay. A total cholesterol level (TCh), high-density (HDL) and low-density lipoprotein (LDL), triglycerides (TG) were assessed by the colorimetric, enzymatic method.

A level of 25(OH)D blood below 30 ng/ml was found in 93 % of the examined persons. In the presence of the allele B in the BsmI polymorphism of the VDR gene, the levels of TCh and TG are significantly lower (p = 0.001) than in the genotype BB. With genotypes bb or Bb in combination with Ff or ff, the level of TCh in the blood plasma is smallest in comparison to other genotypes of polymorphic markers BsmI and FokI of the VDR gene. With genotype bb or bB in combination with FF, the level of HDL is higher (p = 0.048) than in the genotype bb or bB in combination with Ff or ff. In the presence of the allele B in the polymorphism of the VDR gene, the BsmI risk of hypercholesterolemia is 4.3 times higher than in individuals with the genotype bb (OR = 4.3, 95 % CI 1.3; 14.1).

In individuals with CHD and D-hypovitaminosis, the BsmI and FokI polymorphisms of the VDR genes affect the level of TCh and TG and the presence of the allele B with the BsmI polymorphism increases the risk of hypercholesterolemia. 

1. Miettinen M. E., Kinnunen L., Leiviskä J., Keinänen-Kiukaanniemi S., Korpi-Hyövälti E., Niskanen L., Oksa H., Saaristo T., Tuomilehto J., Vanhala M., Uusitupa M., Peltonen M. Association of serum 25-hydroxyvitamin D with lifestyle factors and metabolic and cardiovascular disease markers: population-based cross-sectional study (FIN-D2D). PLoS One, 2014, vol. 9, no. 7, e100235.

2. Verdoia M., Schaffer A., Sartori C., Barbieri L., Cassetti E., Marino P., Galasso G., de Luca G. Vitamin D deficiency is independently associated with the extent of coronary artery disease. European Journal of Clinical Investigation, 2014, vol. 44, no. 7, рр. 634–642.

3. Jorde R., Figenschau Y., Hutchinson M., Emaus N., Grimnes G. High serum 25-hydroxyvitamin D concentrations are associated with a favorable serum lipid profile. European Journal of Clinical Nutrition, 2010, vol. 64, no. 12, pp. 1457–1464.

4. Yankovskaya L. V., Snezhitskiy V. A., Lyalikov S. A., Pludovskiy P., Semyachkina-Glushkovskaya O. V. Positive effects of cholecalciferol supplementation on plasma lipid levels in patients with arterial hypertension. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta [Journal of the Grodno State Medical University], 2015, no. 3, pp. 78–84 (in Russian).

5. Povoroznyuk V. V., Snezhitskiy V. A., Yankovskaya L. V., Maylyan E. A., Reznichenko N. A., Maylyan D. E. Extraskeletal effects of vitamin D: role in the pathogenesis of cardiovascular diseases. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta [Journal of the Grodno State Medical University], 2015, vol. 2, no. 50, pp. 6–14 (in Russian).

6. Zittermann A., Frisch S., Berthold H. K., Gotting C., Kuhn J., Kleesiek K., Stehle P., Koertke H., Koerfer R. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. American Journal of Clinical Nutrition, 2009, vol. 89, no. 5, pр. 1321–1327.

7. Wang H., Xia N., Yang Y., Peng D.-Q. Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials. Lipids in Health and Disease, 2012, no. 20, pp. 11–42.

8. Oh J., Weng S., Felton S. K., Bhandare S., Riek A., Butler B., Proctor B. M., Petty M., Chen Z., Schechtman K. B., Bernal-Mizrachi L., Bernal-Mizrachi C. 1,25-(OH)2 -vitamin inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation, 2009, no. 120, pp. 687–698.

9. Wehmeier K. R., Mazza A., Hachem S., Ligaray K., Mooradian A. D., Wong N. C. W., HaasK M. J. Differential regulation of apolipoprotein A-I gene expression by vitamin D receptor modulators. Biochimica et Biophysica Acta, 2008, vol. 1780, no. 2, рp. 264–273.

10. André G. Uitterlinden, Yue Fang, Joyce B. J. van Meurs, Huibert A. P. Pols, Johannes P. T. M. van Leeuwen. Genetics and biology of vitamin D receptor polymorphisms. Gene, 2004, no. 338, pp. 143–156.

11. Russian guidelines: diagnosis and correction of lipid metabolism disorders in order to prevention and treatment of atherosclerosis. Rossiyskie rekomendatsii, V peresmotrа [Russian guidelines], Moscow, 2012. 25 p. (in Russian).

12. Karonova T. L. Metabolic and molecular genetic aspects of vitamin D metabolism and the risk of cardiovascular disease in women. Abstract of diss. St. Petersburg, 2014. 20 p. (in Russian).

13. Xia Z., Hu Y, Zhang H, Han Z, Bai J, Fu S, Deng X, He Y. Association of vitamin D receptor Fok I and Bsm I polymorphisms with dyslipidemias in elderly male patients with type 2 diabetes. Nan Fang Yi Ke Da Xue Xue Bao, 2014, vol. 34, no. 11, pp. 1562–1568.

14. Ortlepp J. R., Lauscher J., Hoffmann R., Hanrath P., Joost H. G. The vitamin D receptor gene variant is associated with the prevalence of type 2 diabetes mellitus and coronary artery disease. Diabetic Medicine, 2001, vol. 18, no. 10, pp. 842–845.

15. Ortlepp J. R., von Korff A., Hanrath P., Zerres K., Hoffmann R. Vitamin D receptor gene polymorphism BsmI is not associated with the prevalence and severity of CAD in a large-scale angiographic cohort of 3441 patients. European Journal of Clinical Investigation, 2003, vol. 33, no. 2, pp. 106–109.